

**Changes to the CalOptima Medi-Cal Physician Administered Drugs, OneCare Formulary and OneCare Connect Formulary
Pharmacy & Therapeutics Committee Meeting – February 17, 2022**

Effective Dates	Brand Name†	Generic Name	Drug Class	Strength	Dosage Form	Committee Action for CalOptima Medi-Cal Physician Administered Drugs	Committee Action for OneCare/ OneCare Connect
4/1/22	Winlevi	Clascoterone	Acne Vulgaris	1 %	Cream	N/A	Non-Formulary
4/1/22	Kloxxado	Naloxone	Opioid Antagonist	8 mg/0.1 mL	Liquid	N/A	Formulary QL: 2/30 days
4/1/22	Tavneos	Avacopan	Complement Inhibitor	10 mg	Capsule	N/A	PA Required QL: 180/30 days
4/1/22	Tyrvaya	Varenicline tartrate	Dry eye disease	0.03 mg/actuation	Solution	N/A	PA Required QL: 4.2 mL/ 30 days
4/1/22	Tivdak	Tisotumab vedotin-tftv	Antineoplastic	40 mg	Solution	PA Required	PA Required NSO (Part B)
4/1/22	Fyarro	Sirolimus protein bound particles	Antineoplastic	100 mg	Suspension	PA Required	PA Required (Part B)
4/1/22	Lybalvi	Olanzapine-samidorphane malate	Antipsychotic	10-10 mg, 15-10 mg, 20-10 mg, 5-10 mg	Tablet	N/A	PA Required NSO QL: 30/30 days
4/1/22	Exkivity	Mobocertinib	Antineoplastic	40 mg	Capsule	N/A	PA Required NSO QL: 120/30 days
4/1/22	Scemblix	Asciminib	Antineoplastic	20mg, 40 mg	Tablet	N/A	PA Required NSO QL: 300/30 days (40 mg), 60/30 days (20 mg)

N/A=Not Applicable, NSO = New Starts Only, PA = Prior Authorization, QL = Quantity Limit